![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-term impact of HCV eradication after all oral
therapy in patients with clinical significant portal hypertension
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Saturday Parallel session: Clinical impact of HCV cure
S Lens1, E Alvarado-Tapias2, Z Marino1, J Martinez3, MC Londono1, E
LLop4, JI Fortea5, L Ibanez6, R Banares6, A Puente5, A Albillos3, JL
Calleja4, X Torras2, Anna Baiges1, Virginia Hernandez-Gea1, J Bosch1, C
Villanueva2, X Forns1, JC García-Pagan1
1.Liver Unit, Hospital Clinic, Barcelona. Universidad de Barcelona. IDIBAPS. CIBEREHD.
2.Gastroenterology Department, Hospital Santa Creu I Sant Pau, Barcelona
3.Gastroenterology and Hepatology Department, Hospital Ramon y Cajal. Universidad de Alcala. Madrid. CIBEREHD. 4.Liver Unit, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid. 5.Digestive Diseases Department, Marques de Valdecilla University Hospital.IDIVAL. Santander. Spain 6.Liver Unit, Hospital Gregorio Maranón. Madrid
![0416181](../images%20/041618/041618-12/0416181.gif)
![0416182](../images%20/041618/041618-12/0416182.gif)
![0416183](../images%20/041618/041618-12/0416183.gif)
![0416184](../images%20/041618/041618-12/0416184.gif)
![0416185](../images%20/041618/041618-12/0416185.gif)
![0416186](../images%20/041618/041618-12/0416186.gif)
![0416187](../images%20/041618/041618-12/0416187.gif)
![0416188](../images%20/041618/041618-12/0416188.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|